Sponsor or institution
Clinical trials and research at Hackensack University Medical Center
As of November 12, 2026, Find a Trial lists 79 NIH-funded research projects at this institution, with $87.1 million in listed awards. Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 79NIH research projects
NIH-funded research (newest 40 of 79)
Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.
-
Orally accessible antiviral leaders to fight COVID-19 and related coronaviruses
A research effort to fast-track safe, easy-to-take oral drugs that can treat COVID-19 and other coronaviruses by repurposing and optimizing existing antiviral compounds.
-
Metropolitan Antiviral Drug Accelerator Virology Core
A core team across top hospitals and universities is testing antiviral compounds against SARS-CoV-2 and related coronaviruses to identify promising drugs for COVID-19.
-
Broad-spectrum SARS-CoV-2 protease inhibitor for antiviral therapy
Researchers are developing a new small-molecule drug that blocks a key SARS-CoV-2 enzyme, with potential to treat COVID-19 across multiple virus variants.
-
Metropolitan AntiViral Drug Accelerator: Animal Models
A large NIH-funded effort uses animal models to test new antiviral compounds against SARS-CoV-2 and related viruses to move promising leads toward early development.
-
Metropolis AntiViral Drug Accelerator: Pharmacology Core
A dedicated program to speed up promising antiviral drugs by testing their behavior in the body and choosing the best candidates for further development.
-
Metropolitan Antiviral Drug Accelerator
A national program at Hackensack University Medical Center to help develop and optimize small-molecule drugs that may block key SARS-CoV-2 proteins, potentially slowing COVID-19 replication.
-
Metropolitan Antiviral Drug Accelerator (MAVDA)
A national effort to speed up the discovery and development of new antiviral medicines to fight diseases like COVID-19, with a focus on making lead compounds that could become effective treatments.
-
MAVDA: a central hub to discover oral antiviral drugs for COVID-19 and other viruses
A central core facility helps scientists rapidly screen and study potential oral antiviral drugs to fight SARS-CoV-2 and other emerging viruses.
-
Metropolitan AntiViral Drug Accelerator: Administrative Core
A centralized management hub is being built to help move promising antiviral drugs for COVID-19 and similar viruses from discovery toward potential products.
-
Discovery of bacterial antivirals to fight COVID-19 and related viruses
A project aims to find new antiviral compounds produced by bacteria that could help treat infections from SARS-CoV-2 and other coronaviruses.
-
Broad antiviral drugs that target coronaviruses and other viruses
A research program aims to identify small molecules that can block multiple viruses, focusing first on coronaviruses, to help create drugs that can treat future outbreaks.
-
RNA-synthesis inhibitors to fight coronaviruses
A patient-facing look at a research effort to find small molecules that stop how coronaviruses copy their RNA, with the aim of helping current and future patients.
-
Metropolitan AntiViral Drug Accelerator: advancing SARS-CoV-2 therapies
A collaborative program is testing new antiviral compounds to treat COVID-19 by targeting key viral enzymes and supporting early-stage drug development.
-
Metropolitan AntiViral Drug Accelerator
A partnership between academia and industry in New York City/NJ to discover and advance new oral antiviral drugs for COVID-19 and related viruses.
-
Can an Evidence-Based Mental Health Intervention be Used in Home Visiting Programs
A proven mental health program for perinatal women is being adapted to fit into existing home visiting services to help mothers and families.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Celiac and IBD: unlocking how genes influence disease with DNA methylation
A research project aims to use genetic and epigenetic clues to better understand why celiac disease and inflammatory bowel disease affect people differently and how they respond to treatment.
-
Host-plasmid dynamics in ESBL-Klebsiella pneumoniae spread
This grant supports a study of how bacteria carry and share genetic traits that make ESBL-producing Klebsiella pneumoniae hard to treat, with a focus on real patient-derived samples and community infections.
-
CTCF's role in keeping CD8 T cells healthy and ready to fight infections and cancer
A study exploring how a key protein (CTCF) helps maintain CD8+ T cells and their ability to fight viruses and tumors.
-
Nuclear envelope changes and liver cancer risk in chronic liver disease
Aims to understand how changes in the cell’s nuclear envelope may raise the risk of liver cancer in people with chronic liver disease.
-
Therapeutics for drug-resistant bacteria using arylmyxopyronins
Aimed at new antibiotics, this project tests arylmyxopyronins to treat drug-resistant Acinetobacter and other bacteria, potentially offering options when current drugs fail.
-
Oral combination therapy to treat staphylococcal infections using dicloxacillin and P911
A new oral drug combination aiming to safely kill staph infections, including resistant strains, by pairing dicloxacillin with a beta-lactam potentiator for outpatient use.
-
Advanced dual-targeted drug candidate to treat drug-resistant gonorrhea
A new dual-action medicine is being developed to treat serious gonorrhea infections caused by drug-resistant bacteria.
-
Lead optimization and preclinical development of a small molecule to fight Mycobacterium avium infections
A research grant aims to develop a new small-molecule drug to treat infections caused by Mycobacterium avium complex (MAC), which can cause serious lung disease in people.
-
New rifamycin drugs to improve cure rates and shorten treatment for Mab lung infection
A new family of rifamycin antibiotics is being developed to better treat Mycobacterium abscessus lung disease and shorten the time patients need therapy.
-
Animal Model and Microbiology Core: advancing drug candidates against resistant bacteria
A core facility at Hackensack University Medical Center helps scientists quickly test new anti-bacterial drugs using real patient-style bacterial strains and animal infection models.
-
Medicinal Chemistry Core for Antibiotic Drug Discovery
A dedicated Medicinal Chemistry Core will support antibiotic drug discovery by providing synthetic chemistry, computer-aided design, and structure-based optimization to help develop new treatments for resistant bacteria.
-
Pharmacology Core for Accelerating Safe Antibiotics against Drug-Resistant Infections
A core team helps test how new antibiotic candidates behave in the body and in the body’s tissues to reduce drug failures and bring promising treatments for drug-resistant infections closer to patients.
-
Center to speed up antibacterial drugs for hard-to-treat infections
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
Enriching ECHO: Understanding how prenatal exposures and family factors affect kids with health challenges
A national project is studying how prenatal and early-life exposures, plus caregiving and social support, influence health and well‑being in children with and without chronic health challenges.
-
Overcoming beta-lactam resistance in Mycobacterium abscessus complex
This grant tests new ways to make beta-lactam antibiotics work better against tough lung infections caused by Mycobacterium abscessus, especially in people with cystic fibrosis or weakened immune systems.
-
L-Citrulline for BPD-related Pulmonary Hypertension in Preterm Babies
A first-in-human study will test safe and effective doses of L-citrulline given by mouth to stability-preterm infants at risk for lung blood pressure problems.
-
Optimizing rifamycins to treat non-tuberculous lung infections
Aims to make rifamycin antibiotics work better against non-tuberculous mycobacteria (NTM) that cause lung disease.
-
New all-oral treatments for Mycobacterium abscessus lung infections
Trying combinations of new and existing oral antibiotics to find medicines that can kill Mycobacterium abscessus in people with lung infections.
-
Understanding Environmental Factors for Children's Health
This project aims to understand how environmental factors and personal choices during and after pregnancy affect the health and well-being of children, especially those facing health challenges.
-
How the protein ID3 controls donor T cells that cause GVHD and fight leukemia
Researchers are looking at whether changing the activity of a protein called ID3 in donor T cells can lower graft-versus-host disease while keeping those cells able to attack leukemia after a stem cell transplant.
-
Finding hidden DNA changes that affect gene control in multiple myeloma
Researchers are looking for DNA changes outside of genes that may change how genes are turned on or off in people with multiple myeloma.
-
How CD8 T cells become exhausted in long infections and cancer
This project looks at how CD8 (killer) T cells change their three-dimensional genome structure during long-term infections or cancer to help scientists find ways to make them work better for patients.
-
How antifungal drugs and weak immunity change Candida glabrata in the gut
This project looks at how antifungal medicines and immune problems change Candida glabrata in the gut, for people at risk of invasive fungal infections.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.